Mounjaro 15 mg kwikpen

Tirzepatide 15 mg KwikPen is a once-weekly injectable medication used for the treatment of type 2 diabetes and, in certain indications, for chronic weight management. It acts as a dual GIP and GLP-1 receptor agonist, helping to increase insulin secretion when blood sugar levels are high, reduce glucagon release, slow gastric emptying, and suppress appetite. The 15 mg dose is typically the highest maintenance dose after gradual titration and is used to achieve maximum glycemic control and enhanced weight reduction. It may also contribute to improvements in cardiovascular risk factors such as body weight and blood pressure. Common side effects include nausea, vomiting, diarrhea, decreased appetite, and abdominal discomfort, and it should be used under medical supervision.